WLWon-Suk Lee

Won-Suk Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Won-Suk Lee has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Ho Hee Jang

    Department of Biochemistry, College of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon Univerisity, Incheon, Republic of Korea

    2 shared publications
  • Suntaek Hong

    Department of Biochemistry, College of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon Univerisity, Incheon, Republic of Korea

    2 shared publications
  • Dong Hun You

    Gachon Univ, Dept Biol Sci, Coll Sci, Inchon, South Korea

    1 shared publication
  • Hae NA Lee

    Department of Biochemistry, College of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Gachon Univerisity, Incheon, Republic of Korea

    1 shared publication
  • Hye Youn Kim

    Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea

    1 shared publication
  • Jeong-Heum Baek

    Gachon Univ, Dept Surg, Gil Med Ctr, Sch Med, Inchon, South Korea

    1 shared publication

Latest Publications

  • Expression of RNA-binding Motif Protein 3 (RBM3) and Cold-inducible RNA-binding protein (CIRP) Is Associated with Improved Clinical Outcome in Patients with Colon Cancer

    by Ho Hee Jang, Hae NA Lee, So-Young Kim, Suntaek Hong, Won-Suk Lee

    Background: Recent studies have shown a potential role of RNA-binding proteins (RBPs) in a variety of biological pathways, including cancer progression, whilst their expression in various tumor types may be associated with patient prognosis. However, the role of the RBP family members has not been explored in colon cancer and their possible use as prognostic biomarkers is largely unknown. Materials and Methods: To determine the prognostic role of three RBP genes: insulin-like growth factor-binding protein 2 (IGFBP2), RNA-binding motif protein 3 (RBM3), and cold-inducible RNA-binding protein (CIRP) in colon cancer. Results: We examined the RNA expression of IGFBP2, RBM3, and CIRP in 94 human colon cancer samples along with matched normal tissue samples from each patient using quantitative real-time polymerase chain reaction (qRT-PCR). No significant associations were observed between RNA expression of RBPs and the studied clinical features. The estimated 5-year disease-free survival rate was significantly better for patients with higher expression of RBM3 and CIRP, while patient survival was not significantly correlated to IGFBP2 expression. Conclusion: RBM3 and CIRP may be useful prognostic biomarkers of colon cancer.


  • Open Access

    Targeting the PI3K signaling pathway in KRAS mutant colon cancer

    by Suntaek Hong, SoYoung Kim, Hye Youn Kim, Myunghee Kang, Ho Hee Jang, Won‐Suk Lee

    Metastatic colorectal cancer (CRC) patients with v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are resistant to monoclonal antibody that targets the epidermal growth factor receptor such as cetuximab. BKM120 targets phosphatidylinositide‐3‐kinase (PIK3CA), but it is unknown whether BKM120 can reverse cetuximab resistance in KRAS mutant CRC. Human CRC cell lines with KRAS mutations (DLD‐1, HCT116, and LoVo) were used to test the effect of cetuximab, BKM120, and cetuximab plus BKM120 on cell proliferation in vitro and in vivo. BKM120 reduced cell proliferation in a concentration‐dependent manner in the LoVo (PI3KCA wild type) as well as the HCT116 and DLD1 cells (that carry a PI3KCA mutation). BKM120 only inhibited ERK phosphorylation in LoVo cells (PIK3CA wild type), but not in DLD1 or HCT116 cells at a concentration of 1 μmol/L. Treatment with cetuximab and BKM120 significantly reduced the growth of xenograft tumors originating from KRAS mutant cells compared with cetuximab alone (P = 0.034). BKM120 may overcome cetuximab resistance in colon cancer cells with KRAS mutation.


  • Open Access

    Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea and vomiting after laparoscopic gynecologic surgery: a prospective randomized trial

    by Won-Suk Lee, Kwang-Beom Lee, Soyi Lim, Young Gin Chang

    Selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are reported to have potent antiemetic effects for postoperative nausea and vomiting (PONV). The purpose of this study was to prospectively evaluate the efficacy of palonosetron, granisetron, and ramosetron for the prevention of PONV in patients undergoing laparoscopic gynecologic surgery. In this prospective, randomized observational study, 105 healthy female patients who were undergoing laparocopic hystectomy under general anaesthesia were enrolled (clinical trial number: NCT01752374, www.clinicaltrials.gov ). Patients were divided into three groups: the palonostron (0.075 mg i.v.; n = 35), the granisetron group (3 mg i.v.; n = 35), and the ramosetron group (0.3 mg i.v.; n = 35). The treatments were given before the end of surgery. The incidence of PONV, severity of nausea/vomiting, and the use of rescue antiemetic requirements during the first 48 h after surgery were evaluated. The overall incidence of PONV was 33.3 % for this series. The number of complete responders at 48 h after the surgery was 21 (60.0 %) for palonosetron, 24 (68.6 %) for granisetron, and 26 (71.4 %) for ramosetron, representing no statistical difference (P = 0.086). There were no significant differences in the overall incidence of postoperative nausea and vomiting and complete responders for palonosetron, granisetron and ramosetron group. Clinical trial number: NCT01752374 , www.clinicaltrials.gov .


  • Prognostic value of circulating cytokines for stage III colon cancer

    by Won-Suk Lee, Jeong-Heum Baek, Dong Hun You, Myeong Jin Nam